Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
The investment underscores Zynext Ventures' commitment to advancing innovation in critical therapeutic areas.
PENNINGTON, N.J., June 3, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for high-unmet need cancers.
Agenus' lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
"Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. "Our extensive global partner network will also play a key role in supporting Agenus' entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus' programmes and unlock their full potential."
In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs.
Dr. Garo Armen, Chairman and CEO of Agenus, said, "We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL's remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus' commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy."
About Zynext Ventures
Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.
For more details visit: www.zyduslife.com.
LinkedIn: @Zydusuniverse
Instagram: @ZydusUniverse
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients.
For more details visit: www.agenusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company's public filings for additional information regarding potential risks and timelines.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
U.S.-EU trade deal raises questions of how Canada will fair as deadline looms
Watch Japan and the EU have now inked trade deals with the U.S., but how will Canada fair as Trump's deadline looms? CTV's Jeremie Charron has more.
CBC
4 hours ago
- CBC
Trump, EU reach trade deal framework
U.S. President Donald Trump and European Commission President Ursula von der Leyen announced the framework of a new trade deal that includes a 15 per cent tariff on most EU imports.
Calgary Herald
6 hours ago
- Calgary Herald
US, China negotiators meet in Stockholm to extend trade truce
Article content While China has denied its responsibility for the flow of the deadly drug, last month it tightened controls over two chemicals that can be used to make the opioid. Earlier this month, Trump praised those moves. 'China has been helping out,' he told reporters. 'We're talking to them and they're making big steps.' Article content For the US, the recent Chinese actions aren't enough, as such moves were required to comply with United Nations measures, according to a person familiar with the trade talks. Chances of reducing the 20% tariff in this round of talks are very slim, added the person who asked not to be identified discussing sensitive matters, while noting everything could change on Trump's whim. Article content China would be willing to cooperate more on fentanyl, said Sun Chenghao, a professor at Tsinghua University in Beijing. But the US would have to remove the related tariffs, stop blaming Beijing for what it sees as a US domestic problem and provide concrete evidence of crimes, he said. Article content Article content The US business community remains hopeful for progress, with Sean Stein, president of the US-China Business Council, telling Bloomberg TV that movement on fentanyl presents the 'biggest opportunity' in talks. Article content 'That then lowers tariffs on the US side, which then opens the door for China to lower tariffs that lets us sell agriculture, lets us sell airplanes, lets us sell automobiles, that let's us sell energy,' he said. Article content Oil Purchases Article content In his comments announcing the talks, Bessent indicated negotiations can now take on a broader array of topics, potentially including Beijing's continued purchases of sanctioned oil from Russia and Iran. Article content Chinese state media has already pushed back against that idea. 'China won't play along' with such attempts to use China to kill Russia's economy, Lv Xiang, a US expert with the Chinese Academy of Social Sciences last week told the state-run tabloid Global Times. Article content Article content By contrast, China's imports of three major energy products from the US hit almost zero in June, marking the first time in almost three years the Asian nation didn't import any crude oil from its top rival. Deliveries of American crude oil, liquefied natural gas and coal have been subject to Chinese tariffs of 10% to 15% since February. Article content Xi's government has begun rolling back some of its other retaliatory measures since the two sides met last month in London. Crucially, Beijing has boosted shipments of rare earth magnets, while the US relaxed restrictions on sales of less-advanced semiconductors to China. Article content In another potential goodwill gesture, as the Sweden talks were announced this month, China revealed it had suspended an antitrust investigation into the local unit of US chemical manufacturer DuPont de Nemours Inc.
